NCT01435330View on ClinicalTrials.gov

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Insulin Resistance
Interventions
DRUG

BVS857

DRUG

Placebo

Trial Locations (2)

91910

Novartis Investigative Site, Chula Vista

98418

Novartis Investigative Site, Tacoma

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY